Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data Validation
1.6 Data Sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 GLP-1 receptor agonist industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Drug class trends
2.1.4 Route of administration
2.1.5 Application trends
2.1.6 Distribution channel trends
Chapter 3 GLP-1 Receptor Agonist Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic diseases such as diabetes and obesity
3.2.1.2 Increasing R&D activities for developing novel therapeutics
3.2.1.3 Formulation advancements of oral GLP-1 receptor agonists
3.2.1.4 Increasing awareness about diagnosis and treatment options for diabetes
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with few GLP-1 agonist drugs
3.2.2.2 Product recalls by market players
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By route of administration
3.3.3 By application
3.3.4 By distribution channel
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Regulatory landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 GLP-1 Receptor Agonist Market Estimates and Forecast, By Drug Class (USD Million)
5.1 Key trends, by drug class
5.2 Semaglutide
5.3 Dulaglutide
5.4 Liraglutide
5.5 Exenatide
5.6 Other drug classes
Chapter 6 GLP-1 Receptor Agonist Market Estimates and Forecast, By Route of Administration (USD Million)
6.1 Key trends, by route of administration
6.2 Parenteral
6.3 Oral
Chapter 7 GLP-1 Receptor Agonist Market Estimates and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Type 2 diabetes mellitus
7.3 Obesity
7.4 Other applications
Chapter 8 GLP-1 Receptor Agonist Market Estimates and Forecast, By Distribution Channel (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 GLP-1 Receptor Agonist Market Estimates and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Switzerland
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Eli Lilly and Company
10.2 Sanofi
10.3 Novo-Nordisk A/S
10.4 AstraZeneca
10.5 Pfizer, Inc.
10.6 Amgen, Inc.
10.7 Innovent Biologics, Inc.
10.8 PegBio Co., Ltd.
10.9 Sun Pharmaceutical Industries Ltd.
10.10 Boehringer Ingelheim International GmbH
